Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Translational Stroke Research
Published in: Translational Stroke Research 3/2013

Open Access 01-06-2013 | Special Report

RIGOR Guidelines: Escalating STAIR and STEPS for Effective Translational Research

Authors: Paul A. Lapchak, John H. Zhang, Linda J. Noble-Haeusslein

Published in: Translational Stroke Research | Issue 3/2013

Login to get access

Abstract

Stroke continues to be a serious and significant health problem in the USA and worldwide. This article will emphasize the need for good laboratory practices, transparent scientific reporting, and the use of translational research models representative of the disease state to develop effective treatments. This will allow for the testing and development of new innovative strategies so that efficacious therapies can be developed to treat ischemic and hemorrhagic stroke. This article recommends guidelines for effective translational research, most importantly, the need for study blinding, study group randomization, power analysis, accurate statistical analysis, and a conflict of interest statement. Additional guidelines to ensure reproducibility of results and confirmation of efficacy in multiple species are discussed.
Literature
1.
Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, et al. Heart disease and stroke statistics—2010 update: a report from the American Heart Association. Circulation. 2010;121(7):e46–e215.PubMedCrossRef
2.
Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, et al. Executive summary: heart disease and stroke statistics—2010 update: a report from the American Heart Association. Circulation. 2010;121(7):948–54.PubMedCrossRef
3.
Boudreau DM, Guzauskas G, Villa KF, Fagan SC, Veenstra DL. A model of cost-effectiveness of tissue plasminogen activator in patient subgroups 3 to 4.5 hours after onset of acute ischemic stroke. Ann Emerg Med. 2012. doi:10.​1016/​j.​annemergmed.​2012.​04.​020.
4.
Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359(13):1317–29.PubMedCrossRef
5.
Lansberg MG, Bluhmki E, Thijs VN. Efficacy and safety of tissue plasminogen activator 3 to 4.5 hours after acute ischemic stroke: a metaanalysis. Stroke. 2009;40(7):2438–41.PubMedCrossRef
6.
group ISTc, Sandercock P, Wardlaw JM, Lindley RI, Dennis M, Cohen G, et al. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial. Lancet. 2012;379(9834):2352–63. Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov’t.PubMedCrossRef
7.
Fang MC, Cutler DM, Rosen AB. Trends in thrombolytic use for ischemic stroke in the United States. J Hosp Med. 2010;5(7):406–9.PubMedCrossRef
8.
NINDS. Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med. 1995;333(24):1581–7.CrossRef
9.
10.
Wepfer JJ. Observationes anatomicae ex cadaveribus eorum, quos sustulit apoplexia cum exercitatione de eius loco affecto. Schaffhausen, Switzerland: O.A. Waldkirch; 1675.
11.
Gurdjian ES, Gurdjian ES. History of occlusive cerebrovascular disease I. from Wepfer to Moniz. Arch Neurol. 1979;36(6):340–3. Historical Article.PubMedCrossRef
12.
Willis T. Cerebri Anatome: cui accessit nervorum descriptio et usus. London; 1664.
13.
Dechambre A. Dictionnaire Encyclopédique des Sciences Médicales. Paris, France; 1866;18.
14.
Virchow R. Thrombose und Embolie: Gefässenzýndung und Septische Infektion, in Gesammelte Abhandlungen zur wissen schaftlichen Medicin. Frankfurt: a. M., Meidinger, Sohn und Co; 1856.
15.
Bramwell B. Spontaneous meningeal haemorrhage. Edinb Med J. 1886;32:101.
16.
Symonds CP. Spontaneous sub-arachnoid haemorrhage. Proc Royal Soc Med. 1924;17:39–52. Neurol Sect.
17.
Lloyd-Jones D, Adams R, Carnethon M, De Simone G, Ferguson TB, Flegal K, et al. Heart disease and stroke statistics—2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009;119(3):480–6.PubMedCrossRef
18.
Lapchak PA. Hemorrhagic transformation following ischemic stroke: significance, causes, and relationship to therapy and treatment. Curr Neurol Neurosci Rep. 2002;2(1):38–43.PubMedCrossRef
19.
Lyden PD, Zivin JA. Hemorrhagic transformation after cerebral ischemia: mechanisms and incidence. Cerebrovasc Brain Metab Rev. 1993;5(1):1–16.PubMed
20.
Bernstein RA, Del-Signore M. Recent advances in the management of acute intracerebral hemorrhage. Curr Neurol Neurosci Rep. 2005;5(6):483–7.PubMedCrossRef
21.
22.
Lapchak PA. Translational stroke research using a rabbit embolic stroke model: a correlative analysis hypothesis for novel therapy development. Transl Stroke Res. 2010;1(2):96–107. Perspective Review.PubMedCrossRef
23.
Lapchak PA. Emerging therapies: pleiotropic multi-target drugs to treat stroke victims. Transl Stroke Res. 2011;2(2):129–35.PubMedCrossRef
24.
Ginsberg MD. Current status of neuroprotection for cerebral ischemia: synoptic overview. Stroke. 2009;40(3 Suppl):S111–4.PubMedCrossRef
25.
Moskowitz MA, Lo EH, Iadecola C. The science of stroke: mechanisms in search of treatments. Neuron. 2010;67(2):181–98.PubMedCrossRef
26.
Lapchak PA. Neuroprotective and neurotrophic curcuminoids to treat stroke: a translational perspective. Expert Opin Investig Drugs. 2011;20(1):13–22.PubMedCrossRef
27.
Chen J, Chopp M. Neurorestorative treatment of stroke: cell and pharmacological approaches. NeuroRx. 2006;3(4):466–73.PubMedCrossRef
28.
STAIR. Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke. 1999;30(12):2752–8.CrossRef
29.
Turner R, Jickling G, Sharp F. Are underlying assumptions of current animal models of human stroke correct: from STAIRS to high hurdles? Transl Stroke Res. 2011;2(2):138–43.PubMedCrossRef
30.
Cook DJ, Tymianski M. Nonhuman primate models of stroke for translational neuroprotection research. Neurotherapeutics. 2012;9(2):371–9.PubMedCrossRef
31.
Fisher M. Recommendations for advancing development of acute stroke therapies: stroke therapy academic industry roundtable 3. Stroke. 2003;34(6):1539–46.PubMedCrossRef
32.
Fisher M, Hanley DF, Howard G, Jauch EC, Warach S. Recommendations from the STAIR V meeting on acute stroke trials, technology and outcomes. Stroke. 2007;38(2):245–8.PubMedCrossRef
33.
Saver JL, Albers GW, Dunn B, Johnston KC, Fisher M, Consortium SV. Stroke Therapy Academic Industry Roundtable (STAIR) recommendations for extended window acute stroke therapy trials. Stroke. 2009;40(7):2594–600. Congresses Research Support, N.I.H., Extramural.PubMedCrossRef
34.
Albers GW, Goldstein LB, Hess DC, Wechsler LR, Furie KL, Gorelick PB, et al. Stroke Treatment Academic Industry Roundtable (STAIR) recommendations for maximizing the use of intravenous thrombolytics and expanding treatment options with intra-arterial and neuroprotective therapies. Stroke. 2011;42(9):2645–50. Practice Guideline Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov’t.PubMedCrossRef
35.
Shuaib A, Lees KR, Lyden P, Grotta J, Davalos A, Davis SM, et al. NXY-059 for the treatment of acute ischemic stroke. N Engl J Med. 2007;357(6):562–71.PubMedCrossRef
36.
Bath PM, Gray LJ, Bath AJ, Buchan A, Miyata T, Green AR. Effects of NXY-059 in experimental stroke: an individual animal meta-analysis. Br J Pharmacol. 2009;157(7):1157–71.PubMedCrossRef
37.
Feuerstein GZ, Zaleska MM, Krams M, Wang X, Day M, Rutkowski JL, et al. Missing steps in the STAIR case: a translational medicine perspective on the development of NXY-059 for treatment of acute ischemic stroke. J Cereb Blood Flow Metab. 2008;28(1):217–9.PubMedCrossRef
38.
Ginsberg MD. Life after cerovive: a personal perspective on ischemic neuroprotection in the post-NXY-059 era. Stroke. 2007;38(6):1967–72.PubMedCrossRef
39.
Savitz SI. A critical appraisal of the NXY-059 neuroprotection studies for acute stroke: a need for more rigorous testing of neuroprotective agents in animal models of stroke. Exp Neurol. 2007;205(1):20–5.PubMedCrossRef
40.
41.
Pardo Cabello AJ, Bermudo Conde S, Manzano Gamero V, Gomez Jimenez FJ, de la Higuera Torres-Puchol J. Implementation of clinical practice guidelines for acute ischaemic stroke in specialist care centres. Neurologia. 2012. doi:10.​1016/​j.​nrl.​2012.​04.​008.
42.
Sipahi I, Swaminathan A, Natesan V, Debanne SM, Simon DI, Fang JC. Effect of antihypertensive therapy on incident stroke in cohorts with prehypertensive blood pressure levels: a meta-analysis of randomized controlled trials. Stroke. 2012;43(2):432–40.PubMedCrossRef
43.
Kiers L, Davis SM, Larkins R, Hopper J, Tress B, Rossiter SC, et al. Stroke topography and outcome in relation to hyperglycaemia and diabetes. J Neurol Neurosurg Psychiatry. 1992;55(4):263–70. Research Support, Non-U.S. Gov’t.PubMedCrossRef
44.
Baird TA, Parsons MW, Barber PA, Butcher KS, Desmond PM, Tress BM, et al. The influence of diabetes mellitus and hyperglycaemia on stroke incidence and outcome. J Clin Neurosci. 2002;9(6):618–26. Research Support, Non-U.S. Gov’t Review.PubMedCrossRef
45.
46.
Wechsler L, Steindler D, Borlongan C, Chopp M, Savitz S, Deans R, et al. Stem Cell Therapies as an Emerging Paradigm in Stroke (STEPS): bridging basic and clinical science for cellular and neurogenic factor therapy in treating stroke. Stroke. 2009;40(2):510–5. Review.
47.
Savitz SI, Chopp M, Deans R, Carmichael ST, Phinney D, Wechsler L. Stem Cell Therapy as an Emerging Paradigm for Stroke (STEPS) II. Stroke. 2011;42(3):825–9. Congresses.PubMedCrossRef
48.
49.
Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, National Centre for the Replacement R, et al. Animal research: reporting in vivo experiments—the ARRIVE guidelines. J Cereb Blood Flow Metab. 2011;31(4):991–3. Research Support, Non-U.S. Gov’t.PubMedCrossRef
50.
Kilkenny C, Parsons N, Kadyszewski E, Festing MF, Cuthill IC, Fry D, et al. Survey of the quality of experimental design, statistical analysis and reporting of research using animals. PLoS One. 2009;4(11):e7824. Research Support, Non-U.S. Gov’t.PubMedCrossRef
51.
Savitz SI, Lew R, Bluhmki E, Hacke W, Fisher M. Shift analysis versus dichotomization of the modified Rankin scale outcome scores in the NINDS and ECASS-II trials. Stroke. 2007;38(12):3205–12.PubMedCrossRef
52.
Lyden P, Lu M, Jackson C, Marler J, Kothari R, Brott T, et al. Underlying structure of the national institutes of health stroke scale: results of a factor analysis. Stroke. 1999;30:2347.PubMedCrossRef
53.
Metadata
Title
RIGOR Guidelines: Escalating STAIR and STEPS for Effective Translational Research
Authors
Paul A. Lapchak
John H. Zhang
Linda J. Noble-Haeusslein
Publication date
01-06-2013
Publisher
Springer-Verlag
Published in
Translational Stroke Research / Issue 3/2013
Print ISSN: 1868-4483
Electronic ISSN: 1868-601X
DOI
https://doi.org/10.1007/s12975-012-0209-2

Other articles of this Issue 3/2013

Translational Stroke Research 3/2013 Go to the issue

Original Article

Characterisation of Endothelin-1-Induced Intrastriatal Lesions Within the Juvenile and Adult Rat Brain Using MRI and 31P MRS

Original Article

SAHIT Investigators—on the Outcome of Some Subarachnoid Hemorrhage Clinical Trials

Original Article

Suppression of the Rho/Rho-Kinase Pathway and Prevention of Cerebral Vasospasm by Combination Treatment with Statin and Fasudil After Subarachnoid Hemorrhage in Rabbit

Original Article

In Vivo Animal Stroke Models

Original Article

Guidelines for Using Mouse Global Cerebral Ischemia Models

BRIEF COMMUNICATIONS

Polymorphisms in ACVRL1 and Endoglin Genes are Not Associated with Sporadic and HHT-Related Brain AVMs in Dutch Patients